{
  "study_objective": [
    "This is a randomized, double-blind, placebo-controlled, multicenter, Phase 2 study of the efficacy and safety of E/P/A with trilaciclib or placebo therapy for patients with newly diagnosed extensive-stage SCLC.",
    "Study G1T28-05 was originally designed as a Phase 2 clinical study to investigate if myelopreservation, ie, preservation of hematopoietic stem and progenitor cell (HSPC) and immune system function during chemotherapy, by trilaciclib could provide survival benefit to patients receiving a combination of cytotoxic chemotherapy and an immune checkpoint inhibitor."
  ],
  "inclusion_criteria": [
    "Age \u226518 years",
    "Unequivocally confirmed diagnosis of SCLC by histology or cytology, preferably including the presence of neuroendocrine features by immunohistochemistry",
    "Extensive-stage SCLC",
    "At least 1 target lesion that is measurable by RECIST v1.1 (Eisenhauer 2009)",
    "Hemoglobin \u22659.0 g/dL",
    "Absolute neutrophil count (ANC) \u22651.5 \u00d7 109/L",
    "Platelet count \u2265100 \u00d7 109/L",
    "Creatinine \u22641.5 mg/dL or glomerular filtration rate (GFR) of \u226560 mL/minute",
    "Total bilirubin \u22641.5 \u00d7 ULN; < 3 \u00d7 ULN if the patient has documented Gilbert\u2019s disease",
    "AST and ALT \u22642.5 \u00d7 ULN; \u22645 \u00d7 ULN in the presence of liver metastases",
    "ECOG performance status of 0 to 2",
    "Predicted life expectancy of \u22653 months",
    "Contraception: For females: All females of childbearing potential must have a negative serum beta human chorionic gonadotropin (\u03b2-hCG) test result at screening. Females must be either postmenopausal, surgically sterile, or agree to use 2 forms of highly effective contraception during the study and for 6 months following discontinuation of study treatment",
    "For males: Males must be surgically sterile or have a female partner who is either postmenopausal, surgically sterile, or using 2 forms of highly effective contraception as noted above.",
    "Able to understand and sign an informed consent"
  ],
  "exclusion_criteria": [
    "Limited-stage SCLC",
    "Prior chemotherapy for limited or extensive-stage SCLC",
    "Prior treatment with immunotherapies including but not limited to cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies (such as anti-PD-1, anti-PD-L1, CTLA4 therapeutic antibodies)",
    "Presence of symptomatic brain metastases requiring immediate treatment with radiation therapy or steroids",
    "Malignancies other than SCLC within 3 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome",
    "History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan (history of radiation pneumonitis in the radiation field [fibrosis] is permitted)",
    "Active, known, or suspected autoimmune disease that has required systemic treatment in the past 2 years",
    "Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart failure (Class III or IV as defined by the New York Heart Association [NYHA] functional classification system)",
    "Known history of stroke or cerebrovascular accident within 6 months prior to enrollment",
    "Serious active infection at the time of enrollment",
    "Psychiatric illness/social situations that would limit study compliance",
    "Other uncontrolled serious chronic disease or conditions that in the investigator\u2019s opinion could affect compliance or follow-up in the protocol",
    "Known human immunodeficiency virus (HIV), known active Hepatitis B or Hepatitis C",
    "Radiotherapy to any site within 2 weeks prior to enrollment",
    "Receipt of any investigational medication within 4 weeks prior to enrollment",
    "Administration of a live attenuated vaccine within 4 weeks before enrollment or anticipation that such a live attenuated vaccine will be required during the study",
    "Patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration.",
    "Hypersensitivity to any of the components of the formulation of etoposide or etoposide phosphate",
    "Hypersensitivity to carboplatin or other platinum-containing compounds, or mannitol",
    "History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins",
    "Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies",
    "Legal incapacity or limited legal capacity",
    "Pregnant or lactating women"
  ],
  "primary_endpoints": [
    "duration of severe (Grade 4) neutropenia in Cycle 1",
    "occurrence of severe (Grade 4) neutropenia"
  ],
  "secondary_endpoints": [
    "Overall survival",
    "objective response and PFS (as assessed by RECIST version 1.1)"
  ]
}